Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this retrospective, observational study is to compare the profit of BAV and TAVI in different subtypes of serve aortic stenosis.
The Balloon Aortic Valvuloplasty (BAV) is a catheter-based intervention, which can be used for dilatation of serve aortic stenosis. With this minimally invasive intervention an increase of the aortic valve area (AVA) and cardiac ejection fraction (EF), decrease of transvalvular gradients and ultimately a symptom relief should be achieved. The required effect is temporary and a definitive treatment should be aspired in suitable patients. Therefor Transcatheter Aortic Valve Replacement (TAVR) is available.
Following the guidelines of the European Society of Cardiology for the management of valvular heart disease from 2017, the aortic stenosis can be divided into different subtypes by using haemodynamic parameters: High-gradient AS (HG-AS), Low-Flow-Low-Gradient AS (LFLG-AS) and paradoxical Low-Flow-Low-Gradient (pLFLG-AS). Patients with LFLG-AS are suspected to have a poorer prognosis when treated curative as well as when treated palliative medicamentous, because these patients show coronary and myocardial restrictions more frequently in addition to the valvular disease.
The aim of the study is to compare safety and effectiveness of balloon aortic valvuloplasty as a bridging therapy and transcatheter aortic valve replacement as a definitive treatment in HG-AS, LFLG-AS and pLFLG-AS patients to verify whether the subtypes of aortic stenosis profit equally from these interventions.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| High-Gradient Aortic Stenosis (HG-AS) | (Pmean >40mmHg, AVA <1cm^2, Vmax >4m/s) |
| |
| Low-Flow-Low-Gradient Aortic Stenosis (LF-LG) | (Pmean <40mmHg, AVA <1cm^2, Vmax <4m/s, EF <50%) |
| |
| Paradoxe Low-Flow Low Gradient Aortic Stenosis (pLF-LG AS) | Pmean <40mmHg, AVA <1cm^2, Vmax < 4m/s, EF >50%) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BAV | Procedure | BAV |
|
| Measure | Description | Time Frame |
|---|---|---|
| All-cause Mortality | 1-Year post BAV | |
| Post-Procedure Hemodynamic Changes | dPmean, dPmax, AVA, Vmax, EF; Evaluation by using the first echocardiographic parameters after BAV / TAVR | 24 - 72 h after procedure |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients with myocardial infarction | Evaluation by using the VARC-2 definition | 30 days after intervention |
| Number of patients with stroke | Evaluation by using the VARC-2 definition |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients in the heart failure program of the University of Duesseldorf
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Tobias Zeus, MD | Div. of Heinrich-Heine-University, Div. of Cardiology, Pulmonary Disease and Vascular Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Division of Cardiology, Pulmonary Disease and Vascular Medicine | Düsseldorf | 40225 | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001024 | Aortic Valve Stenosis |
| ID | Term |
|---|---|
| D000082862 | Aortic Valve Disease |
| D006349 | Heart Valve Diseases |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| BAV + TAVR | Procedure | BAV + TAVR |
|
| SAVR | Procedure | Surgical aortic valve replacement (SAVR) |
|
| 30 days after intervention |
| Number of patients with bleeding complications | Evaluation by using the VARC-2 definition | 30 days after intervention |
| Number of patients with acute kidney injury | Evaluation by using the VARC-2 definition | 30 days after intervention |
| Number of patients with vascular complications | Evaluation by using the VARC-2 definition | 30 days after intervention |
| D014694 |
| Ventricular Outflow Obstruction |